Abstract. Embryonic stem (ES) cells are expanded versions of the inner cell mass cells that compose the early mammalian blastocyst. Components derived from ES cells may contain various bioactive materials (BM) helpful for early preimplantation embryo growth. In this study, we examined the effect of human ES cell derived BM (hES-BM) on in vitro culture of bovine embryos. When bovine parthenogenetic day 2 embryos were cultured in 10% hES-BM, a significantly higher embryo development rate (44.3%) and increased cell numbers were observed relative to control medium containing 3 mg/ml BSA (19.5%; P<0.01). Among the various concentrations (5, 10 and 15%) and days of treatment (2 or 4 days) tested, 10% hES-BM treatment for 4 days provided the best culture environment to support the growth of bovine embryos in vitro (P<0.05). Little difference was observed between 10% hES-BM and 10% FBS treatment in the examined parthenogenetic or in vitro fertilized embryos, although the hES-BM group developed at a slightly better rate. However, the ICM cell numbers were significantly higher in the hES-BM group in irrespective of embryo origin (P<0.05). In addition, the relative levels of pluripotency (Oct4, × 1.8 fold; Nanog. × 3.3 fold), embryogenesis (Stat3, × 2.8 fold; FGF4, × 18.8 fold; E-cad, × 2.0 fold) and growth (Glut5, × 2.6 fold) genes were significantly higher in the 10% hES-BM group than in the 10% FBS group (P<0.05), while the levels of other genes (Bax, Bcl2, MnSOD and Connexin43) were not different. This is the first report examining the positive effects of hES-BM on bovine embryo development in vitro. Based on our results, we conclude that hES-BM can be used as a new protein supplement for bovine preimplantation embryo development.
(J. Reprod. Dev. 57: [346] [347] [348] [349] [350] [351] [352] [353] [354] 2011) uccessful preimplantation embryo development in vitro requires a culture environment comparable to in vivo conditions; specifically, this entails using an effective basic culture medium, various protein supplements and a coculture system with a somatic cell feeder layer [1, 2] . Almost all media used for bovine embryo development in vitro contain bovine serum albumin (BSA) and fetal bovine serum (FBS) as a source of protein, and recently, serum replacement (SR) or a synthetic serum substitute have also been used [3, 4] . Serum provides energy substrates, amino acids, vitamins, growth factors and heavy metal chelators [5] . Serum also has a biphasic effect, inhibiting early cleavage divisions and accelerating the development of morula and blastocysts [6] . However, the undefined mixture in serum may result in highly variable developmental rates in vitro and affect the high incidence of apoptosis observed in in vitro produced embryos. Moreover, the presence of serum over a prolonged period of time has been shown to alter the expression patterns of various genes [7, 8] . Nevertheless, while serum is an important protein supplement for bovine embryo development in vitro, a finding for the better protein supplement is needed to support in vitro culture and provide conditions more similar to the in vivo environment.
Embryonic stem (ES) cells are expanded from the inner cell mass (ICM) cells that compose the early mammalian blastocyst. These cells are pluripotent, retain long-term proliferative potential in an undifferentiated state and can differentiate into derivatives of all three embryonic germ layers under in vitro differentiation culture conditions or in an in vivo environment [9] . Thus, bioactive material derived from robust, young ES cells (ES cell derived bioactive material, ES-BM) may supply more reliable and supportive factors for the growth of preimplantation embryonic cells. However, stable bovine embryonic stem cells have yet to be established.
Production of reconstructed embryos by somatic cell nuclear transfer depends on successful oocyte activation and a culture environment enhancing their developmental potential. Our team [10] reported a surviving clone of an endangered Black Cattle species native to Jeju Island last year, and thus we have an stable activation technique capable of producing a reconstructed embryo (>80%).
To find better culture conditions for reconstructed embryos, in this study, as a new trial, we tested the effect of ES-BM prepared from an undifferentiated hES cell line (JNU-hES-01, established at Jeju National University) on the development of bovine parthenogenetic embryos in vitro. Bovine parthenogenetic embryos were grown either in the presence of hES-BM, BSA or FBS, and the embryo development rate, total cell number and ICM cell number in the blastocysts were examined. Also, in vitro produced parthenogenetic embryos grown in the presence of either hES-BM or FBS were analyzed for the relative abundance of gene transcripts in 10 developmentally important categories, such as pluripotency, embryogenesis, growth and apoptosis. Finally, we examined the effect of hES-BM on in vitro developmental capacity of bovine in vitro fertilized (IVF) embryos.
Materials and Methods

Chemicals and reagents
All chemicals and reagents were purchased from Sigma Chemical (St. Louis, MO, USA) unless otherwise stated.
Oocyte collection and in vitro maturation (IVM)
Bovine ovaries were collected from a local abattoir and transported to the laboratory within 2 to 4 h in phosphate buffered saline (PBS) at 37-38 C. Cumulus oocyte complexes (COCs) were retrieved from antral follicles 2-6 mm in diameter with a 19-gauge needle mounted on a 10-ml syringe. COCs with a minimum of 3 layers of cumulus cells were selected and washed twice with HEPES buffered Tyrode's medium. Groups of ten COCs were cultured in 50-μl droplets of maturation medium (TCM-199, Gibco, Grand Island, NY, USA) supplemented with 10% FBS (Gibco), 0.2 mM sodium pyruvate, 1 μg/ml FSH (Folltropin-V; Bioniche Animal Health, Belleville, ON, Canada), 10 μg/ml LH (Leutropin; Bioniche Animal Health), 1 μg/ml estradiol-17β and 25 μg/ml gentamycin. Droplets were covered with mineral oil and incubated in the presence of 5% CO2, 5% O2 and 90% N2 at 38.8 C.
Preparation of human embryonic stem cell derived bioactive material (hES-BM)
JNU-hES-01 cells (15-20 passages), a human embryonic stem (hES) cell line established at Jeju National University using a modified Park's method [11] , were maintained in an undifferentiated state by culturing the cells on a 10 μg/ml mitomycin C-treated STO cell feeder layer (ATCC, USA) in hES cell culture medium [80% Dulbecco's Modified Eagle's Medium (DMEM) Nutrient Mixture F-12 (1:1, Gibco), 20% KnockOut serum replacement (Gibco), 0.1 mM β-mercaptoethanol, 1% nonessential amino acids and 4 ng/ml human basic fibroblast growth factor (hbFGF, KOMA Biotech, Inc)]. To generate hES-BM, large, expanded hES colonies (6-7 days after subculture) were recovered by treatment with 0.5 mg/ml collagenase IV for 5 min, dissociated into small clumps by mechanical dissection and then washed twice with hES medium. Small hES clumps (100-500 cells/clump) were seeded approximately 45-50 clumps per square onto Matrigel (1:20, Becton, Dickinson and Company, Bedford, MA, USA) coated plates and cultured in conditioned medium (CM) prepared from STO cells containing 8 ng/ml hbFGF. Culture supernatant was harvested from expanded, confluent (>90%) hES cells grown in a feeder-free environment, and this supernatant comprised the hES-BM. STO-CM was prepared as follows: 10 μg/ml mitomycin-C treated STO cells were seeded at 50,000 cells/cm 2 in medium containing 90% DMEM and 10% FBS (Hyclone, Logan, UT, USA). One day later, the medium was replaced with hES culture medium. STO-CM was collected daily for 5 days and filtered using a 0.22-μm filter.
Production of parthenogenetic embryos and in vitro culture (IVC)
At 22 h post-IVM, oocytes were fully denuded of cumulus cells using 0.1 mg/ml hyaluronidase and mechanical pipetting. The oocytes were activated in 5 μM Ca-ionomycin for 5-min and then cultured in 2.5 mM 6-dimethylaminopurin for 3 h. After washing, the treated oocytes were cultured in CR1aa medium with 3 mg/ml FAF-BSA for 2 days and were then grown in experimental or control medium (CR1aa supplemented with 3 mg/ml FAF-BSA, 10% FBS or 5%, 10% or 15% hES-BM) from day 4 to 8 according to the experimental design. Cells were maintained in 5% CO2, 5% O2 and 90% N2 at 38.8 C.
Production of IVF embryos and in vitro culture (IVC)
For production of IVF embryos, COCs were transferred into TL-STOCK medium and inseminated with 2 μl of highly motile sperm (25×10 6 spermatozoa/ml) recovered from frozen-thawed bull semen separated on a discontinuous 90% and 45% Percoll column (GE Healthcare, Bio-Sciences AB, Uppsala, Sweden). Two microliters each of heparin (2 μg/ml) and PHE (18.2 M penicillamine, 9.1 M hypotaurine and 1.8 M epinephrine) were also added in a 44-μl IVF drop. For in vitro culture, after 44 ± 2 h of incubation, cleaved embryos were incubated in CR1aa medium containing 3 mg/ml of FAF-BSA until day 4. Embryos were then transferred into CR1aa medium containing 10% FBS or 10% hES-BM until day 8.
Differential staining of blastocysts
Zona intact blastocysts were first incubated in 500 μl of 1% Triton X-100 and 100 μg/ml propidium iodide diluted in TL-HEPES for up to 30 sec, immediately transferred into 500 μl of 25 μg/ml bisbenzimide (Hoechst 33258) diluted in absolute ethanol and then stored at 4 C in the dark. One day later, the blastocysts were transferred into glycerol to remove excessive stain. The embryos were then mounted onto a glass microscope slide in a drop of glycerol, gently flattened with a coverslip and examined using an epifluorescence microscope (Olympus).
Extraction of mRNA
For real-time RT-PCR analysis, mRNA was prepared from blastocysts using magnetic beads (Dynabeads mRNA Purification Kit; Dynal, Oslo, Norway) according to the manufacturer's instructions. Briefly, in each treatment group, fifteen in vitro produced day 8 blastocysts were resuspended in 100 μl lysis/binding buffer (100 mM Tris-HCl, pH 7.5, 500 mM LiCl, 10 mM EDTA, pH 8.0, 1% LiDS and 5 mM DTT) and vortexed at room temperature for 5 min to lyse the tissue. A 50-μl aliquot of an oligo(dT)25 magnetic-bead suspension was added, and the samples were incubated at RT for 5 min. The hybridized mRNA and oligo (dT) beads were washed twice using wash buffer A (10 mM Tris-HCl, pH 7.5, 0.15 M LiCl, 1 mM EDTA and 1% LiDS) and then washed once with wash buffer B (10 mM Tris-HCl, pH 7.5, 0.15 M LiCl and 1 mM EDTA).
Samples of mRNA were eluted from beads in 15 μl of double-distilled DEPC-treated water.
Real-time RT-PCR quantification
Extraction of mRNA was performed as described above, and standard cDNA was synthesized using an oligo (dT) primer and SuperScript Reverse Transcriptase (Invitrogen, Carlsbad, CA, USA). Real-time RT-PCR was performed using the primer sets shown in Table 5 in a Bio-Rad Chromo4 real-time RT-PCR machine. In all experiments, histone H2a mRNA served as an internal standard. The threshold cycle (Ct) value represents the cycle number at which the sample fluorescence rises statistically above the background noise. To monitor the reactions, we followed the protocol described in the DyNAmo SYBR green qPCR kit, which contains a modified Tbr DNA polymerase, SYBR Green, optimized PCR buffer, 5 mM MgCl2 and a dNTP mix that includes dUTP (Finnzyme Oy, Espoo, Finland). For the PCR protocol, the cycling conditions were 95 C for 15 min, followed by amplification and quantification cycles that were repeated 40 times at 94 C for 30 sec, 50 or 56 C for 1 min and 72 C for 1 min. The reactions were subject to a single fluorescence measurement, a melting curve program of 65-95 C with a heating rate of 0.2 C/sec and continuous fluorescence measurement. Samples were then cooled to 12 C. SYBR Green fluorescence was measured after the extension step. PCR products were then analyzed by generating a melting curve. Since the melting curve of a product is sequence specific, it can be used to distinguish nonspecific from specific PCR products. To do this, it is necessary to determine the crossing points (CP) for each transcript, which are defined as the points at which fluorescence rises appreciably above the background noise. Gene expression was quantified by the 2-ddCt method [12] . The sizes of RT-PCR products were confirmed by gel electrophoresis on 2% agarose gels stained with ethidium bromide, and bands were visualized by exposure to ultraviolet light.
Experimental design
Experiment 1. Effect of hES-BM on in vitro development of bovine parthenogenetic embryos: In vitro produced bovine parthenogenetic day 2 embryos (≥2-4 cells) were cultured in CR1aa medium containing 3 mg/ml FAF-BSA (control) or 10% hES-BM until embryonic day 8. The in vitro development rates of day 8 blastocysts were examined, and the blastocysts were differentially stained to determine the effect of hES-BM treatment on the number of total cells and ICM cells. Experiment 2. Effect of hES-BM treatment days on in vitro development of bovine parthenogenetic embryos: In vitro produced bovine parthenogenetic day 2 (≥2-4 cells, hES-BM-1) or day 4 (≥8 cells, hES-BM-2) embryos were cultured in CR1aa containing 10% hES-BM until embryonic day 8. In control groups, day 2 embryos were cultured in CR1aa supplemented with 3 mg/ml FAF-BSA. The embryo development rates and cell numbers were examined.
Experiment 3. Effect of hES-BM concentration on in vitro development of bovine parthenogenetic embryos: In vitro produced bovine parthenogenetic day 4 (≥8 cells) embryos were cultured in CR1aa containing 5%, 10% or 15% hES-BM until embryonic day 8. In control groups, embryos were cultured in CR1aa supplemented with 3 mg/ml FAF-BSA. The embryo development rates and cell numbers were examined.
Experiment 4. Comparison of FBS or hES-BM effect on in vitro development of bovine parthenogenetic embryos:
In vitro produced bovine parthenogenetic day 4 (≥8 cells) embryos were cultured in CR1aa medium containing 10% FBS (control), 10% STO-CM or 10% hES-BM until embryonic day 8. The embryo development rates and cell numbers were examined. Also, the relative mRNA expression levels of 10 candidate genes (Oct4, Nanog, Stat3, FGF4, Connexin43, E-cad, Bcl2, Bax, MnSOD and Glut5) were examined in day 8 blastocysts produced from 10% FBS and 10% hES-BM.
Experiment 5. Comparison of FBS or hES-BM effect on in vitro development of bovine IVF embryos: In vitro fertilized day 4 (≥8 cells) embryos were cultured in CR1aa medium containing 10% FBS (control) or 10% hES-BM until embryonic day 8. The embryo development rates and cell numbers were examined.
Statistical analysis
In all experiments, the data were compiled from at least three independent replicates. Binominal data from the cell cleavage and blastocyst development rates were converted to percentages. The number of ICM and TE cells are expressed as the mean ±SD. Scores representing embryo developmental rates, ICM and TE cell numbers and the relative gene expression levels were evaluated by analyses of variance with SPSS (version 16) using one-way ANOVA with randomized block analysis (Linear mixed model). P values ≤0.05 or ≤0.01 were considered significant.
Results
Effect of hES-BM on bovine parthenogenetic embryo development
As indicated in Table 1 , 69.6% of the day 2 embryos (≥ 2-4 cells, Fig. 1A ) in the control group developed to day 4 (≥ 8 cell, Fig. 1C ), 44.2% developed to day 6 (≥morula) and 19.5% developed to day 8 (≥blastocyst, Fig. 1E ). In contrast, 82.6% of the 10% hES-BM treatment group day 2 embryos (Fig. 1B) developed until day 4 (Fig. 1D) , and 70.4% and 44.3% developed to day 6 and 8, respectively (Fig. 1F) . These embryo development rates were significantly higher than those in the control group at all developmental stages (P<0.05 or P<0.01). To examine the effect of hES-BM on total number of cells and the number of ICM cells, day 8 blastocysts in the control and treatment groups were differentially stained ( Fig. 1G-H) . The mean total cell number of the control group was significantly small (58.3 ± 11.5, × 2.27 fold) relative to that of the 10% hES-BM treatment group (132.2 ± 14.7; P<0.01). In addition, in the 10% hES-BM treatment group, the ICM cells presented a very compacted morphology, and their mean number was significantly higher (30.0 ± 12.7, × 2.44 fold) than that of the control (12.3 ± 6.4; P<0.05).
Effect of hES-BM treatment days on bovine parthenogenetic embryo development
As presented in Table 2 , 48.3% and 20.8% of the control group day 2 embryos were developed to day 6 and 8, respectively. However, embryos cultured in CR1aa containing 10% hES-BM from day 2 (hES-BM-1) or day 4 (hES-BM-2) until day 8 showed signif-icantly higher developmental rates (62.1 and 42.7% for hES-BM-1 and 73.6 and 51.2% for hES-BM-2, respectively) compared with the control (P<0.01). However, there were no significant differences between the hES-BM treatment groups, although the embryonic development rates were slightly higher in the hES-BM-2 group than in the hES-BM-1 group. In addition, the hES-BM treatment groups showed significantly higher total cell numbers compared with the control (53.2 ± 11.5 for the control versus 126.3 ± 15.2 for hES-BM-1 and 133.2 ± 17.3 for hES-BM-2, P<0.01).
Significant differences were observed in the ICM cell numbers (13.1 ± 5.3 for the control versus 30.0 ± 11.4 for hES-BM-1 and 33.9 ± 13.7 for hES-BM-2; P<0.05). Based on these results, in subsequent experiments, we decided to begin hES-BM treatment on day 4 of in vitro bovine embryo culture.
Effect of hES-BM concentration on bovine parthenogenetic embryo development
To determine the best hES-BM concentration, we tested 5%, 10% and 15% hES-BM using day 4 embryos (≥8-cells; Table 3 ). The embryo development rate at day 8 was the best in the 10% hES-BM (63.3%) treatment group among the treatment groups (P<0.05). However, in the other hES-BM treatment groups (5 or 15%), the day 8 blastocyst production rates (46.7 or 50.0%) were better than the rates observed in the control group (22.8%, P<0.05). In addition, 10% hES-BM treatment yielded the highest total cell and ICM cell numbers (125.3 ± 12.3 and 32.0 ± 13.6) among the treatment groups tested (control, 55.8 ± 10.1 and 13.1 ± 5.3; 5% hES-BM, 89.4 ± 10.2 and 16.2 ± 10.1; 15% hES-BM, 90.0 ± 12.0 and 19.0 ± 14.5 for total cell number and ICM cell number, respectively; P<0.05).
Comparison of FBS or hES-BM effect on bovine parthenogenetic embryo development
When the effects of 10% FBS or 10% hES-BM treatment on bovine embryo development from day 4 until day 8 (Table 4) were examined, there was no difference in the development rate between embryos cultured in CR1aa supplemented with 10% FBS (53.6%, Fig. 2A ) and those cultured with 10% hES-BM (62.5%, Fig. 2B ). Although there was no difference in the total cell number counts between the two groups, the ICM cells of the 10% hES-BM treatment group appeared to be presented very compacted, and their mean number (37.3 ± 6.5) was significantly higher than that in the control 10% FBS treatment group (18.7 ± 8.5; P<0.05; Fig. 2C and  D) . In comparison with the 10% hES-BM treatment group, the 10% STO-CM treatment group showed significantly low embryo development rates and ICM cell numbers (P<0.05). Semiquantitative gene expression was also compared using in vitro produced day 8 blastocysts recovered from the 10% FBS and 10% hES-BM treatment groups. The relative abundance of Oct4 (pluripotency, × 1.8 fold), Nanog (pluripotency, × 3.3 fold), Stat3 (cavitation, × 2.8 * Control: culture in CR1aa medium containing 3 mg/ml FAF-BSA from embryonic day 2 until day 8. hES-BM 10%: culture in CR1aa medium containing 10% hES-BM from embryonic day 2 until day 8. ** P<0.01 for x-y, and P<0.05 for a-b. Fig. 1 . Morphology of the in vitro development of bovine parthenogenetic embryos cultured in control CR1aa medium or medium containing 10% hES BM. Embryos were cultured in CR1aa containing 3 mg/ml FAF-BSA (control group, A, C, E and G) or 10% hES-BM (10% hES-BM group, B, D, F and H) from embryonic day 2 (A and B) through to day 4 (C and D) or day 8 (E and F). G and H show representative day 8 blastocysts in the control and 10% hES-BM treatment groups, respectively, stained by a differential labeling method.
fold), FGF4 (implantation, × 18.8 fold), E-cad (biogenesis of trophectoderm, × 2.0 fold) and Glut5 (growth, × 2.6 fold) expression was significantly higher in the 10% hES-BM group compared with the 10% FBS group (P<0.05; Fig. 3 ), while the levels of other genes (Connexin 43, Bcl2, Bax and MnSOD) did not differ between the two groups.
Effect of FBS or hES-BM on bovine IVF embryo development
To examine the effect of 10% hES-BM treatment on bovine IVF embryo development, day 4 embryos were cultured until day 8 (Table 5) , there was no difference in the development rate between embryos cultured in CR1aa supplemented with 10% FBS (54.4%) and those cultured with 10% hES-BM (57.9%). Also, there was no difference in the total cell number counts between the two groups, while the mean number of ICM cells of the 10% hES-BM treatment group (45.0 ± 8.6) was significantly higher than that of the control 10% FBS treatment group (25.2 ± 10.4; P<0.05). *Control: culture in CR1aa medium containing 3 mg/ml FAF-BSA from embryonic day 2 until day 8. hES-BM-1: in CR1aa medium containing 10% hES-BM from embryonic day 2 until day 8. hES-BM-2: culture in control medium at embryonic day 2 and then in CR1aa medium containing 10% hES-BM from day 4 until day 8. ** P<0.01 for x-y, and P<0.05 for a-b. 
Discussion
These results demonstrate that hES-BM can be used for bovine embryo development in vitro as a new protein supplement to replace serum. Treatment with hES-BM resulted in significantly higher rates of bovine parthenogenetic embryo development and increased total cell and ICM cell numbers compared with the BSA control group (P<0.01), which were slightly better than the results obtained for the FBS treatment group. In addition, a similar effect was found in bovine IVF embryos. However, it was especially clear that the in vitro produced embryos in the hES-BM treatment group were more compacted, had higher numbers of ICM cells than the other treatment groups and had many trophectoderm cells. In addition, these effects on embryo development were apparent in the hES-BM-mediated alterations in gene expression. Compared with the FBS treatment group, the relative abundances of two pluripotency-related genes (Oct4 and Nanog), a cavitation gene (Stat3), an implantation gene (FGF4), a trophectoderm biogenesis gene (Ecad) and a growth gene (Glut-5) were significantly higher in the hES-BM treatment group (P<0.05).
In this study, we harvested hES-BM from an expanded culture of undifferentiated hES cells. ES cells are an artificially expanded version of ICM cells, and thus, we hypothesized that cultured ES cell medium may contain many kinds of nutrient factors, cytokines and cell growth factors helpful for early pre0.implantation embryo growth. As shown in supplementary Fig. 1 , our hES cells presented typical ES cell morphology (Suppl Fig. 1A-1 ) and expressed alkaline phosphatase (Suppl Fig. 1A-2 ) and an ES cell surface marker (SSEA-4, Suppl Fig. 1A-3) . Also, we confirmed that our hES cells were a normal XY line by karyotype analysis (Suppl Fig. 1B) and had a STR-genotype using 16 international human locus markers (D8S1179, D21S11, D7S820, CSF1PO, D3S1358, TH01, D13S317, D16S539, D2S1338, D19S433, vWA, TPOX, D18S51, D5S818, FGA and Amelogenin; Suppl Fig. 1C ). Prior to harvesting hES-BM, hES cells (Suppl Fig. 1A-4) were cultured in a feeder-free environment with STO conditioned medium using an extracellular matrix material (Matrigel). Early embryos or ES cells have pluripotency, and this characteristic is controlled by expression level of many transcription factors (such as Oct4, Sox2, Nanog and Stat3). In a previous study [13] , we reported that d-hES cell feeder also supports mouse preimplantation embryo development in vitro/in vivo, and these results may be due to the cells supplying a variety of nutrients (such as metabolites, glycoprotein, signal transcripts, growth factors and cytokines) and important other components (LIF, hCG) for embryonic development. LIF is a cytokine Fig. 3 . Relative mRNA expression of candidate genes in bovine day 8 blastocysts. The bars with different superscripts within a panel differ significantly from each other (P<0.05). Error bars indicate the standard deviation. In the control treatment group, day 2 embryos were cultured in CR1aa medium supplemented with 3 mg/ml FAF-BSA and then in CR1aa containing 10% FBS from embryonic day 4 until day 8. In the 10% hES-BM treatment group, day 2 embryos were cultured in CR1aa medium supplemented with 3 mg/ml FAF-BSA and then CR1aa containing 10% hES-BM from embryonic day 4 until day 8. b *10% FBS: culture in CR1aa medium containing 3 mg/ml FAF-BSA at day 2 and then in CR1aa medium supplemented with 10% FBS from embryonic day 4 until day 8. 10% hES-BM: culture in CR1aa medium containing 3 mg/ml FAF-BSA at day 2 and then in CR1aa supplemented with 10% hES-BM from embryonic day 4 until day 8. ** P<0.05 for a-b.
belonging to the IL-6 family and is normally expressed in the trophectoderm of the developing embryo, while its receptor, LIFR, is expressed throughout the ICM during embryogenesis. Also, it has been reported that LIF is an important factor for the decidualization of the uterine stroma and is directly involved in blastocyst implantation together with other factors (LIFR and gp 130) [14] . In addition, we analyzed the constituents of hES-BM in several categories, such as inorganics, proteins, lipids, hormones and carbohydrates. As described in supplementary Table 1 , compared with medium, hES-BM contains more total protein, albumin, insulin and citrate and less total cholesterol, free fatty acid, phospholipid, total lipid, glucose, pyruvic acid and lactic acid. The results showed that the hES-BM total protein content was 2.13 g/dl and that the value was lower (× 1.64 fold) than that of FBS (3.5 g/ dl, data by Gibco). However, the insulin content of hES-BM (120.3 μU/ml) was significantly higher (× 17.6 fold) than that of FBS (6.8 μU/ml). Insulin promotes the uptake of glucose and amino acids [15] , and the high content of insulin in hES-BM might have a positive effect on bovine embryo development. Also, osmolarity of hES-BM was 340 mOSM and the pH was 8.0, while those of FBS were 314 and 7.2, respectively. Thus, the osmolarity and pH of CR1aa medium containing 10% hES-BM are estimated to be 273 mOSM and 7.45 pH, respectively. In addition, we confirmed that the hES-BM was not contaminated with mycoplasmas (genitalium and pneumoniae), viruses (HIV Ab, HBV Ag and HCV Ab), bacteriophages and endotoxins. Even though serum supplementation results in a higher rate of blastocyst development, component concentration differences according to serum lot variation in embryo development can cause alterations in the embryo ultrastructure, impaired compaction, abnormal blastulation, large offspring syndrome, aberrant mRNA expression profiles and greater incidence of stillbirth and death after birth [16] [17] [18] [19] . In this study, we used hES-BM recovered from a permanent hES cell line has prolonged growing potential, and so, we mentioned that our source is very stable. On the other hand, other teams have reported that a chemically defined medium (such as SOF) is very attractive for culture of bovine preimplantation embryos, although the percentages of developing embryos are lower than our results [20, 21] .
In our initial study, day 2 embryos were assigned to either the control group cultured in CR1aa medium containing 3 mg/ml FAF-BSA or the 10% hES-BM treatment group. The addition of hES-BM to the culture medium significantly affected on the rate of embryo development and increased cell numbers compared with embryos grown in BSA (P<0.01). The percentage of embryos that stopped developing at or before the morula stage was significantly greater in the BSA supplemented group, while the embryo development rate of the hES-BM treatment group was very similar to that of the FBS treatment group. Notably, however, we observed that the hES-BM treated embryos had a higher number of ICM cells and that their morphology was very compacted. These results suggest that hES-BM is a potent serum alternative for embryo development in vitro. Given that in early embryonic stages excessive nutrients may inhibit embryo development, we evaluated the effect of hES-BM treatment on embryo growth when used as a media supplement from day 2 or day 4 until day 8. There were no significant differ- ences between the two groups, but similar to serum treatment, the day 4 hES-BM treatment group tended to develop at a higher rate than the day 2 treatment group, and under all conditions, embryo development was significantly higher in the experimental group compared with the control group (P<0.01). In addition, the optimal concentration of hES-BM was determined by treating cells with 5-15% hES-BM. Embryos treated with 10% hES-BM showed the highest cell numbers. These results demonstrate that the 10% hES-BM concentration and day 4 treatments might best support preimplantation bovine embryo development in vitro. These results are very similar to the optimal conditions for serum addition.
Compared with the effect of FBS on the late embryo development (≥day 4), the 10% hES-BM treatment also resulted in similar but slightly better development rates (60.2 vs. 55.9%) and total cell numbers (125.0 ± 22.0 vs. 103.7 ± 13.6) than the 10% serum. Moreover, the ICM cell numbers in the 10% hES-BM treatment group were significantly higher than in the 10% FBS treatment group (37.0 ± 12.5 vs. 18.2 ± 7.6; P<0.05). Morphologically, there was no difference in the developmental stage between the two groups at embryonic day 8, although blastocyst expansion tended to occur a little faster in the 10% FBS treatment group than in the 10% hES-BM treatment group from day 6 to day 7. In addition, it was noteworthy that the blastocysts grown in hES-BM group shown increased formation of tight junctions, as the total size of the blastocyst was small, but it contained many cells. Even though in most bovine embryo development experiments, serum is used as a standard protein supplement, as shown in the differential stained morphology of Fig. 2 , the appearance of the blastocyst of the 10% FBS group was very rough and the cell arrangement was disorderly, while that of the 10% hES-BM group was more closely packed and had an orderly cell arrangement. Also, we confirmed that this effect did not originate from the STO-CM but originated from the hES-BM in a comparison experiment. Therefore, this proved that addition of hES-BM may improve bovine parthenogenetic embryo developmental potential relative to FBS. Also, we confirmed that the hES-BM has the same effect on the development of bovine in vitro fertilized embryos as that of parthenogenetic embryos (data not shown).
Fertilized bovine oocytes divide continuously and undergo a series of distinct morphological changes, such as compaction, cavitation and blastocoel formation. These rapid changes in morphology require well-orchestrated expression of genes from the maternal and/or embryonic genome [22] . Prolonged in vitro culture has been shown to be associated with abnormal embryonic and fetal growth and development as well as reduced calving rates [23] . Culture conditions, in particular the presence of serum, is thought to be involved in these abnormalities [24] . The transcription of developmentally important genes is affected by the in vitro environment and may possibly lead to perturbation of differentiation and organogenesis. By simultaneous amplification of an internal standard, it is possible to determine the relative abundance of desired transcripts [25] . In this study, we examined the relative expression of ten developmentally important genes in the 10% FBS and 10% hES-BM treatment groups, Oct4, Nanog, Stat3, E-cad, Glut5, FGF4, Bax, Bcl2, MnSOD and Connexin 43. Oct4, a transcription factor associated with embryonic cell differentiation, can be detected in both the ICM and the trophectoderm (TE) of a blastocyst [26] . Nanog is a homeobox-containing transcription factor with an essential function in maintaining the pluripotent cells of the ICM and in the derivation of ES cells [27] . Interestingly, compared with the 10% FBS treatment group, significantly higher levels of Oct-4 (× 1.8 fold) and Nanog (× 3.3 fold) transcripts were detected in blastocysts that developed in the presence of 10% hES-BM. This result coincides with the significantly higher number of ICM cells and the slight increase in the number of TE cells in the 10% hES-BM treatment group relative to the 10% FBS group. Stat3 has been suggested to be involved in determination of the animal pole of the oocyte and in establishment of the ICM and TE cell lineages in preimplantation mouse and human embryos [28] . In the 10% hES-BM treated bovine embryos, the high levels of Stat3 (2 × 2.8 fold) might also affect polarization and the subsequent allocation of ICM and TE cells. FGF-4 is essential for trophoblast growth and is directly responsible for survival of the blastocyst ICM [29] . In this study, highly increased but variable FGF-4 gene expression was detected in the 10% hES-BM (× 8.8 fold) treatment group compared with the 10% FBS treatment group. Also, the TE morphogenesis and biogenesis gene, E-cad (× 2.0 fold), was highly expressed in the 10% hES-BM treatment group compared with the 10% FBS treatment group. These results demonstrate that the transcription of ICM and TE development-related genes was increased by the addition of hES-BM in bovine embryos produced in vitro.
In addition to these genes, glucose transporter expression is also developmentally regulated. Within in vitro derived bovine preimplantation embryos, the expression of facilitated glucose transporters (Glut1-5 and 8) is variable, while Glut1, Glut3, Glut8 and SGLT-I are expressed at all stages. Glut4 transcripts are first detected at the blastocyst stage, while transcription of the fructose transporter Glut5 begins at the 8-/16-cell stage [30] . In this study, we found that Glut-5 was expressed more highly following 10% hES-BM treatment (× 2.6 fold) compared with 10% FBS treatment. The gap junction protein connexin 43, by contrast, is necessary for maintenance of compaction that is required for subsequent blastocyst formation [31] . Gap junction formation and communication is essential for growth, cellular differentiation, and embryonic development [32] . Connexin 43 expression did not differ between the 10% hES-BM and 10% FBS treatment groups. In addition, the relative expression ratios of the proapoptotic gene (Bax), antiapoptotic gene (Bcl2) and oxidative stress gene (MnSOD) were not different between the 10% hES-BM and 10% FBS treatment groups.
Based on these data, we conclude that hES-BM treatment has a positive effect on bovine embryo development as reflected by the high expression of genes important in embryo development (Oct4, Nanog, Stat3, Fgf4, E-cad and Glut5). These results indicate that ES-BM can be used in preimplantation embryo development as a new protein supplement to replace serum, although it leaves a new assignment for the establishment of bovine ES cells.
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